Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
We have an active research program in gastrointestinal cancers including clinical trials, epidemiologic, and translational studies. We would like to establish a biospecimen bank linked to useful clinical information in order to learn more about diagnostic, predictive and prognostic markers for gastrointestinal cancers.
PRIMARY OBJECTIVES:
1. To collect and store tumor and normal tissue (previously collected paraffin embedded or frozen specimen) and blood in patients with gastrointestinal (GI) cancers.
SECONDARY OBJECTIVES:
- Collect detailed clinical information via a patient questionnaire that includes demographic, socioeconomic, lifestyle, family, past medical, medication and cancer histories
- Collect details about the tumor specimen extracted from patient charts.
| Condition | Intervention |
|---|---|
|
Gastrointestinal Neoplasms Gynecologic Cancers Gynecologic Cancers Cervical Cancer Gastric (Stomach) Cancer Gastro-Esophageal(GE) Junction Cancer Gastrointenstinal Stromal Tumor (GIST) Colon/Rectal Cancer Colon/Rectal Cancer Colon Cancer Colon/Rectal Cancer Rectal Cancer Colon/Rectal Cancer Anal Cancer Anal Cancer Hepatobiliary Cancers Hepatobiliary Cancers Liver Pancreatic Cancer |
Procedure: Blood Draw Procedure: Frozen Tumor Specimens |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Collection of Biospecimen and Clinical Information in Patients With Gastrointestinal Cancers |
- None: Biospecimen will be collected for future research. [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
This study requires that we obtain archived tumor and normal tissue and blood.
| Enrollment: | 0 |
| Study Start Date: | January 2010 |
| Estimated Study Completion Date: | January 2099 |
| Estimated Primary Completion Date: | January 2099 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patients with gastrointestinal cancer.
Inclusion Criteria:1. Patients are eligible if they have a histologically proven gastrointestinal cancer (esophageal, gastroesophageal junction, gastric, small intestine, appendix, colon, rectum, anus, liver, gallbladder, bile ducts, pancreas, neuroendocrine, and GI stromal tumor).
2. 18 years of age or older
3. Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:None
Contacts and Locations| United States, California | |
| Stanford University School of Medicine | |
| Stanford, California, United States, 94305 | |
| Principal Investigator: | Teri A Longacre M.D. | Stanford University |
More Information
No publications provided
| Responsible Party: | Stanford University |
| ClinicalTrials.gov Identifier: | NCT01031056 History of Changes |
| Other Study ID Numbers: | SU-09092009-3840, GI0004 |
| Study First Received: | December 10, 2009 |
| Last Updated: | May 24, 2012 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Anus Neoplasms Neoplasms Colonic Neoplasms Rectal Neoplasms Uterine Cervical Neoplasms Esophageal Diseases Gastrointestinal Neoplasms Digestive System Neoplasms Pancreatic Neoplasms Colorectal Neoplasms Intestinal Neoplasms Neoplasms by Site Digestive System Diseases Gastrointestinal Diseases |
Intestinal Diseases Anus Diseases Rectal Diseases Colonic Diseases Uterine Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Uterine Cervical Diseases Uterine Diseases Genital Diseases, Female Endocrine Gland Neoplasms Pancreatic Diseases Endocrine System Diseases |
ClinicalTrials.gov processed this record on May 16, 2013